Compounds > n(delta)-(5-methyl-4-oxo-2-imidazolin-2-yl)ornithine
Page last updated: 2024-10-15

n(delta)-(5-methyl-4-oxo-2-imidazolin-2-yl)ornithine

Description

N(delta)-(5-methyl-4-oxo-2-imidazolin-2-yl)ornithine: RN given for (L)-isomer; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135625302
CHEMBL ID4085254
SCHEMBL ID8372251
MeSH IDM0280684

Synonyms (20)

Synonym
tu 185
n5-(5-hydro-5-methyl-4-imidazolon-2-yl) l-ornithine
149204-50-2
tu-185
n5-(4,5-dihydro-4-methyl-5-oxo-1h-imidazol-2-yl)-l-ornithine
l-ornithine, n5-(4,5-dihydro-4-methyl-5-oxo-1h-imidazol-2-yl)-
n(delta)-(5-methyl-4-oxo-2-imidazolin-2-yl)ornithine
SCHEMBL8372251
AKOS028109258
J-008566
1356932-16-5
bdbm50249566
n~5~-(4-hydroxy-5-methyl-1,5-dihydro-2h-imidazol-2-ylidene)ornithine
DTXSID10933577
(2s)-2-amino-5-[(4-methyl-5-oxoimidazolidin-2-ylidene)amino]pentanoic acid
(2s)-2-amino-5-((4-methyl-5-oxo-4,5-dihydro-1h-imidazol-2-yl)amino)pentanoic acid
(2s)-2-amino-5-((5-methyl-4-oxo-4,5-dihydro-1h-imidazol-2-yl)amino)pentanoic acid
CHEMBL4085254 ,
mgh3_methylglyoxal-derived hydroimidazolone 3
STARBLD0008298

Toxicity

ExcerptReference
" In addition to dose-response and glial protection, experiments were also conducted to determine whether toxic effects were due to apoptosis."( Beta-amyloid toxicity in embryonic rat astrocytes.
Assis-Nascimento, P; Jarvis, KM; Montague, JR; Mudd, LM, 2007)

Dosage Studied

ExcerptReference
" BetaA toxicity was measured in septal glia, via a dose-response experiment, by quantifying the effects of three different doses (0."( Beta-amyloid toxicity in embryonic rat astrocytes.
Assis-Nascimento, P; Jarvis, KM; Montague, JR; Mudd, LM, 2007)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Advanced glycosylation end product-specific receptorHomo sapiens (human)Kd0.03000.03000.03650.0430AID1475138
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (46)

Processvia Protein(s)Taxonomy
response to hypoxiaAdvanced glycosylation end product-specific receptorHomo sapiens (human)
microglial cell activationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of T cell mediated cytotoxicityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of protein phosphorylationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
inflammatory responseAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cell adhesionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cell surface receptor signaling pathwayAdvanced glycosylation end product-specific receptorHomo sapiens (human)
learning or memoryAdvanced glycosylation end product-specific receptorHomo sapiens (human)
response to woundingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
glucose mediated signaling pathwayAdvanced glycosylation end product-specific receptorHomo sapiens (human)
neuron projection developmentAdvanced glycosylation end product-specific receptorHomo sapiens (human)
negative regulation of interleukin-10 productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of chemokine productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of interleukin-1 beta productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of interleukin-12 productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of interleukin-6 productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of tumor necrosis factor productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of heterotypic cell-cell adhesionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of activated T cell proliferationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
transcytosisAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of JNK cascadeAdvanced glycosylation end product-specific receptorHomo sapiens (human)
astrocyte activationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of synaptic plasticityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
induction of positive chemotaxisAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of NF-kappaB transcription factor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of monocyte chemotactic protein-1 productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
protein localization to membraneAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of spontaneous synaptic transmissionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
transport across blood-brain barrierAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of long-term synaptic potentiationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
negative regulation of long-term synaptic potentiationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
negative regulation of long-term synaptic depressionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of p38MAPK cascadeAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of non-canonical NF-kappaB signal transductionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of aspartic-type endopeptidase activity involved in amyloid precursor protein catabolic processAdvanced glycosylation end product-specific receptorHomo sapiens (human)
negative regulation of blood circulationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of endothelin productionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
response to amyloid-betaAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cellular response to amyloid-betaAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of monocyte extravasationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of CD4-positive, alpha-beta T cell activationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
positive regulation of dendritic cell differentiationAdvanced glycosylation end product-specific receptorHomo sapiens (human)
regulation of inflammatory responseAdvanced glycosylation end product-specific receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
amyloid-beta bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
transmembrane signaling receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
scavenger receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
protein bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
signaling receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
identical protein bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
S100 protein bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
protein-containing complex bindingAdvanced glycosylation end product-specific receptorHomo sapiens (human)
advanced glycation end-product receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
molecular adaptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
laminin receptor activityAdvanced glycosylation end product-specific receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (7)

Processvia Protein(s)Taxonomy
fibrillar centerAdvanced glycosylation end product-specific receptorHomo sapiens (human)
extracellular regionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
plasma membraneAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cell surfaceAdvanced glycosylation end product-specific receptorHomo sapiens (human)
apical plasma membraneAdvanced glycosylation end product-specific receptorHomo sapiens (human)
cell junctionAdvanced glycosylation end product-specific receptorHomo sapiens (human)
postsynapseAdvanced glycosylation end product-specific receptorHomo sapiens (human)
plasma membraneAdvanced glycosylation end product-specific receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1475138Binding affinity to human C-terminal His-tagged RAGE domain V (24 to 125 residues) expressed in Escherichia coli BL21(DE3) by tryptophan fluorescence assay2017Journal of medicinal chemistry, 09-14, Volume: 60, Issue:17
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (20.00)18.2507
2000's3 (60.00)29.6817
2010's1 (20.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
pyruvaldehyde
Pyruvaldehyde: An organic compound used often as a reagent in organic synthesis, as a flavoring agent, and in tanning. It has been demonstrated as an intermediate in the metabolism of acetone and its derivatives in isolated cell preparations, in various culture media, and in vivo in certain animals.. methylglyoxal : A 2-oxo aldehyde derived from propanal.		1.99102-oxo aldehyde;
propanals		Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
quinolinic acid
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.. pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.. quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.		3.2510pyridinedicarboxylic acidEscherichia coli metabolite;
human metabolite;
mouse metabolite;
NMDA receptor agonist
ornithine
Ornithine: An amino acid produced in the urea cycle by the splitting off of urea from arginine.. ornithine : An alpha-amino acid that is pentanoic acid bearing two amino substituents at positions 2 and 5.		2.9440non-proteinogenic L-alpha-amino acid;
ornithine		algal metabolite;
hepatoprotective agent;
mouse metabolite
arginine
Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.		1.9910arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid		biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical
n-acetyl-l-arginine
N-acetyl-L-arginine: has effect on convulsive seizures. N(alpha)-acetyl-L-arginine : An N-acetyl-L-amino acid that is L-arginine in which one of the hydrogens attached to the nitrogen is replaced by an acetyl group.		1.9910N-acetyl-L-amino acidhuman metabolite
matrine
[no description available]		3.2510alkaloid
epothilone a
Epothilones: A group of 16-member MACROLIDES which stabilize MICROTUBULES in a manner similar to PACLITAXEL. They were originally found in the myxobacterium Sorangium cellulosum, now renamed to Polyangium (MYXOCOCCALES).		2.0510epothilone;
epoxide		antineoplastic agent;
metabolite;
microtubule-stabilising agent;
tubulin modulator
ixabepilone
[no description available]		2.05101,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle		antineoplastic agent;
microtubule-destabilising agent
fps-zm1
FPS-ZM1: a neuroprotective agent and RAGE receptor antagonist; structure in first source		3.2510
ConditionIndicatedRelationship StrengthStudiesTrials
Degenerative Diseases, Central Nervous System
[description not available]		03.0610
Benign Neoplasms
[description not available]		03.0610
Cardiovascular Diseases
Pathological conditions involving the CARDIOVASCULAR SYSTEM including the HEART; the BLOOD VESSELS; or the PERICARDIUM.		03.0610
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.		03.0610
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		03.0610
Neurodegenerative Diseases
Hereditary and sporadic conditions which are characterized by progressive nervous system dysfunction. These disorders are often associated with atrophy of the affected central or peripheral nervous system structures.		03.0610
Breast Cancer
[description not available]		02.0510
Metastase
[description not available]		02.0510
Breast Neoplasms
Tumors or cancer of the human BREAST.		02.0510
Neoplasm Metastasis
The transfer of a neoplasm from one organ or part of the body to another remote from the primary site.		02.0510